Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treate
- PDF / 650,733 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 44 Downloads / 190 Views
RESEARCH ARTICLE
Dynamic evaluation of neutrophil‑to‑lymphocyte ratio as prognostic factor in stage III non‑small cell lung cancer treated with chemoradiotherapy V. Palomar‑Abril1 · T. Soria‑Comes1 · S. T. Campos2 · M. M. Ureste1 · V. G. Bosch3 · I. C. M. Maiques1 Received: 12 March 2020 / Accepted: 12 May 2020 © Federación de Sociedades Españolas de Oncología (FESEO) 2020
Abstract Purpose Locally advanced non-small cell lung cancer (LA-NSCLC) is frequently treated with chemoradiotherapy (CRT). Despite the efforts, long-term outcomes are poor, and novel therapies have been introduced to improve results. Biomarkers are needed to detect early treatment failure and plan future follow-up and therapies. Our aim is to evaluate the role of dynamics of neutrophil-to-lymphocyte ratio (NLR) in patients with locally advanced NSCLC treated with CRT. Methods We retrospectively reviewed patients diagnosed with LA-NSCLC receiving definitive CRT at our center from 2010 to 2015. Baseline and post-treatment NLR were collected from our center database. NLR was dichotomized (threshold = 4) and patients were divided into two groups based on the variation from baseline to post-treatment NLR. The prognostic role and association with response were examined with logistic regression and multivariate Cox regression model, respectively. Results Ninety-two patients were included. Our analysis shows that NLR after treatment is associated with response to treatment [OR in the multivariate analysis 4.94 (1.01–24.48); p value = 0.048]. Furthermore, NLR and ECOG are independent prognostic factors for progression-free survival (PFS) and overall survival (OS). Specifically, PFS was 25.79 months for the good prognosis group and 12.09 for the poor prognosis group [HR 2.98 (CI 95% = 1.74–5.10), p
Data Loading...
